INT39007

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.10
First Reported 1985
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 3
Disease Relevance 0.94
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (App) Golgi apparatus (App) plasma membrane (App)
extracellular matrix organization (App) DNA binding (App) cytoplasm (App)
Anatomy Link Frequency
pituitary 4
astrocytes 2
App (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Gabapentin 1 83.08 Quite High
cytokine 1 37.84 Quite Low
opiate 2 37.20 Quite Low
antagonist 2 36.64 Quite Low
narcan 10 35.68 Quite Low
imagery 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Syndrome 121 98.50 Very High Very High Very High
Stress 4 92.80 High High
Parkinson's Disease 4 91.96 High High
Cancer 1 76.24 Quite High
Gonadal Disease 2 75.00 Quite High
Generaliased Trisomy 1 50.24 Quite High
Congenital Anomalies 4 32.88 Quite Low
Cognitive Disorder 4 29.84 Quite Low
Stroke 2 19.64 Low Low
Disease 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In DS astrocytes, energy depletion leads to abnormal APP metabolism and altered APP secretion, both of which can be prevented by treatment with antioxidants [22].
Negative_regulation (prevented) of Localization (secretion) of APP in astrocytes associated with syndrome
1) Confidence 0.10 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2996288 Disease Relevance 0.79 Pain Relevance 0.08
The inhibitor of hepatic lipoprotein release, 4-aminopyrazolo-(3,4-d)-pyrimidine (4-APP), has been shown to reduce testosterone production via impairment of pituitary gonadotropin secretion rather than through decreased cholesterol availability.
Negative_regulation (reduce) of Localization (release) of 4-APP in pituitary
2) Confidence 0.05 Published 1985 Journal Endocrinology Section Abstract Doc Link 3886368 Disease Relevance 0.07 Pain Relevance 0
The inhibitor of hepatic lipoprotein release, 4-aminopyrazolo-(3,4-d)-pyrimidine (4-APP), has been shown to reduce testosterone production via impairment of pituitary gonadotropin secretion rather than through decreased cholesterol availability.
Negative_regulation (inhibitor) of Localization (release) of 4-APP in pituitary
3) Confidence 0.05 Published 1985 Journal Endocrinology Section Abstract Doc Link 3886368 Disease Relevance 0.07 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox